Did you know cirrhosis, a disease primarily associated with the liver, can significantly affect your brain? This might come as a surprise to many, but it’s an unfortunate reality for those grappling with this disease. When cirrhosis progresses, it can give rise to hepatic encephalopathy (HE), a serious decline in brain function. As the liver’s capability to remove toxins from the blood diminishes, these toxins can accumulate and impact the brain, leading to Overt Hepatic Encephalopathy (OHE), a severe form of HE. It’s a daunting journey from liver to brain, but we at Research Works are striving to rewrite the narrative.

Introducing our Phase 3 clinical trial, Study RNLC3132, an endeavor designed to delay the onset of OHE in liver cirrhosis patients. This randomized, double-blind, placebo-controlled study aims to explore the safety and effectiveness of a promising treatment, Rifaximin SSD-40mg. Our goal isn’t just to mitigate the disease but to enhance the quality of life for those living with cirrhosis.

We are eager to make a difference, but we need your assistance. If you or a loved one has been diagnosed with liver cirrhosis and meets our eligibility criteria, consider participating in this pivotal study.